Drug intelligence / Profile preview

TREG-AI-2

Development stage: Preclinical
Lead developer: TregTherapeutics
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics

Overview

TREG-AI-2 is a preclinical-stage tolerogenic immunotherapy being developed by TregTherapeutics (exclusively licensed from East Carolina University) for the treatment of systemic autoimmune diseases (specifically designated as Systemic Autoimmune Disease 2). Developed using the proprietary TILAC (Tolerance Induction via Linked Adjuvant/Cytokine conjugate) platform, TREG-AI-2 consists of an alum-based adjuvant conjugated to an anti-inflammatory cytokine. The therapy is designed to shift the dendritic cell microenvironment from immunogenic to tolerogenic signaling, promoting the expansion of antigen-specific regulatory T cells (Tregs) to restore immune tolerance and suppress pathogenic inflammation without causing systemic immunosuppression.

Beyond the preview

Go deeper on TREG-AI-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TREG-AI-2.

Explore the full profile